The Centers for Medicare and Medicaid Services (CMS) is currently considering an amendment proposal to the Massachusetts Medicaid (MassHealth) waiver. If approved, this waiver could have a significant impact on access to treatments, especially innovative medications, for those in Massachusetts Medicaid. This waiver has the potential to set a terrible precedent for Medicaid programs across the country.
The Epilepsy Foundation is particularly concerned about aspects of the proposal related to access to medications. One proposal would create a closed formulary that would ensure coverage of just one drug per class, while another proposal would limit access to innovative new therapies approved by the FDA via expedited pathways by subjecting some new medications to an additional review to further assess efficacy. These changes could limit affordable access to epilepsy medications, and risk the health of people with epilepsy who rely on Massachusetts Medicaid.
In October 2017, the Epilepsy Foundation submitted several comments to CMS on the MassHealth waiver amendment. Read the comments below.
Comments from Epilepsy Foundation and Epilepsy Foundation of New England:
Comments from Epilepsy Foundation and 10 rare epilepsy organizations:
Comments from 222 patient organizations, including the Epilepsy Foundation, and several of our local affiliates and chapters that particularly highlighted concerns with the closed formulary aspect of the proposal:
On August 21, 2017, the Epilepsy Foundation submitted comments to the state Department of Health and Human Services Office of Medicaid, expressing concerns with the proposed amendment. Read our letter below.